Teewinot Life Sciences Corp.

12005 Whitmarsh Lane
Tampa
Florida
33626
United States

Tel: 813-803-6300

About Teewinot Life Sciences Corp.

Teewinot Life Sciences is a global biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid based therapies. Headquartered in Tampa, Florida, Teewinot manufactures and licenses technology to make cost effective, pharmaceutically pure cannabinoids as an industry leader in support of advancing medical research and product development. Teewinot’s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Jeffrey M. Korentur

19 articles about Teewinot Life Sciences Corp.

Teewinot Life Sciences to Participate at the 31st Annual Piper Jaffray Healthcare Conference in New York

11/25/2019

Teewinot Life Sciences Corporation announced Michael Luther Ph.D., Chief Executive Officer, will participate on the Future of Cannabinoid Biosynthesis Panel at the 31st Annual Piper Jaffray Healthcare Conference in New York being held from December 3rd – 5th, 2019 at the Lotte New York Palace.
Teewinot Announces Availability of Cannabinol for Commercial Cannabinoid Market

10/17/2019

Teewinot Life Sciences Corporation announced the availability of high purity CBN in kilogram quantities produced using its CannSynthesis® chemical synthesis process.
BioSpace Movers and Shakers, May 24

5/24/2019

Biopharma companies from across the globe strengthen their leadership teams with key executive appointments.
Teewinot Announces New Pharmaceutical Subsidiary

10/9/2018

Furthers Mission to Address Unmet Therapeutic and Wellness Needs Across the Globe
Teewinot Life Sciences Corporation Announced Today Grant Of A Canadian Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

9/4/2018

Furthers Mission to Address Unmet Therapeutic and Wellness Needs Across the Globe
Teewinot Life Sciences Corporation Announced Today Grant of a U.S. Patent with Claims to Cannabinoid Formulations

8/28/2018

Furthers Mission to Address Unmet Therapeutic and Wellness Needs Across the Globe
Teewinot Life Sciences Corporation's Subsidiary, Teewinot Technologies, Ltd., Announced Today: Grant of a New Patent With Broad Claims to Biosynthetic Production of Cannabinoids

2/6/2018

The claims of the '292 patent cover biosynthetic production of cannabinoids and cannabinoid analogs.
Teewinot Life Sciences Corporation's Subsidiary, Teewinot Technologies, Ltd. Announced Today: Grant of a New Patent With Broad Claims to Biosynthetic Production of Cannabinoid Pharmaceuticals

1/22/2018

Teewinot Life Sciences and its wholly owned Irish subsidiary Teewinot Technologies announced today the grant of U.S. Patent No. 9,861,609.
Teewinot Life Sciences Corporation's Subsidiary, Teewinot Technologies, Ltd. Announced Today: Grant of a New Patent with Broad Claims to Biosynthetic Production of Cannabinoid Pharmaceuticals

1/22/2018

Teewinot Life Sciences and its wholly owned Irish subsidiary Teewinot Technologies announced today the grant of U.S. Patent No. 9,861,609.
Teewinot Life Sciences Corporation, a Global Leader in Pharmaceutical Cannabinoid Production, to Present at CBI's Biopharma Forum on Cannabis-Based Therapies

11/27/2017

Teewinot announced today it will be presenting at CBI's Biopharma Forum on Cannabis-Based Therapies conference on Thursday, November 30th in Denver, CO.
Teewinot Life Sciences Announces New Cannabis Genome Research Program

5/22/2017
Teewinot Life Sciences, A Global Leader In Pharmaceutical Cannabinoid Production, Secures $12.3 Million Series B Round

5/1/2017
Teewinot Life Sciences And Noramco Sign Letter Of Intent To Produce Cannabinoids With CannSynthesis Biocatalysis Technology

3/20/2017
Teewinot Life Sciences' Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant Of An Important U.S. Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

3/7/2017
Teewinot Life Sciences Announces Breakthrough Commercial Production Of The Cannabinoid Varin Series

2/21/2017
Teewinot Life Sciences Announces Breakthrough Commercial Production Of The Cannabinoid Varin Series

2/14/2017
Teewinot Life Sciences' Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures A New U.S. Patent For Biosynthesis Of Cannabinoids

1/3/2017
Teewinot Life Sciences' Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures A New U.S. Patent Covering An Apparatus For Biosynthetic Production Of Authentic THCA, CBDA And CBCA Cannabinoids

12/6/2016
Teewinot Life Sciences Secures First U.S. Patent Covering An Apparatus For The Biosynthetic Production Of Authentic THCA, CBDA And CBCA Cannabinoids

7/19/2016